Project Grant R01AI198708
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.14 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Trustees of Columbia University in the City of New York, Health Sciences Division, for research on regulatory T cell (Treg) memory in human tissues. The award, obligated on February 6, 2026, with completion targeted for January 31, 2030, supports fundamental immunology research...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a $821,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period May 1, 2026 through April 30, 2031. The award funds systematic research to advance understanding of genetic diseases of the immune system (GDIS) through functional variant mapping and precision medicine development. The project will...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a Project Grant of $761,840 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 5, 2025, with a completion date of July 31, 2030. This award supports research to characterize and functionally evaluate plasma cell infiltrates in cardiac allograft vasculopathy (CAV), the leading cause of morbidity and mortality...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $452,835 Project Grant to the University of Pittsburgh under the Allergy and Infectious Diseases Research program (CFDA 93.855) with an award date of February 2, 2026, and completion date of January 31, 2028. This research initiative, titled "Reversing Graft Rejection by Targeting Innate Immune Memory with Novel Nanobiologics," focuses on developing innovative therapeutic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $246,750 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective August 1, 2025, with completion targeted for July 31, 2027, supports research examining the transcriptional and functional identity of human T follicular helper (TFH) cells...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University $239,135 on August 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a magnetics-based platform for high-speed mapping of tissue mechanical properties. The project, which will be conducted in New York and is scheduled for completion by July 31, 2027, addresses a critical technical limitation in understanding how...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $462,000 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and optimize FAB-fragment drug conjugates (FDCs) as targeted immunosuppressive delivery systems for organ transplant applications. The project, which commenced February 4, 2026 and concludes January 31, 2028, will design and characterize an...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a $452,375 Project Grant (CFDA 93.855: Allergy and Infectious Diseases Research) effective February 6, 2026, through January 31, 2028. The award supports clinical and translational research focused on in vivo profiling of Chimeric Autoantibody Receptor T Cell (CAART) therapy for Muscle-Specific Tyrosine Kinase (MuSK) myasthenia gravis. The...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $764,591 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a five-year research project running from August 1, 2025, through July 31, 2030. This research initiative investigates the differential regulation of cell cycle entry and apoptosis in cytolytic lymphocytes, specifically...
- Federal Grant Award Summary The University of Chicago received a $766,265 Project Grant award dated July 23, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on transplantation tolerance mechanisms through June 30, 2030. The grant funds investigative research into the role of regulatory T cells (Tregs) in acquiring and maintaining conventional T cell (Tconv) anergy in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $836,711 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) on May 1, 2026, for a five-year research initiative spanning through April 30, 2031. Under the Allergy and Infectious Diseases Research program (CFDA 93.855), this award supports investigator-initiated biomedical research examining whether selective Major Histocompatibility Complex (MHC) Class II matching between donor and recipient decreases rejection and promotes regulatory tolerance in intestinal transplantation (ITX). The research deliverables include preclinical investigation and translational research utilizing a swine orthotopic ITX model to evaluate whether MHC Class II sharing extends rejection-free survival of intestinal grafts through minimization of rejection via expansion of regulatory T cells. The study builds upon preliminary findings demonstrating that partial MHC Class II allele sharing decreases rejection and promotes donor-specific hyporesponsiveness in graft tissue, with potential applications to advance ITX as a therapeutic option for patients with intestinal failure. The research outputs will generate scientific knowledge and methodological advances intended to improve transplantation outcomes and inform clinical protocols for donor-recipient matching in intestinal transplantation.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $836.7k | 4/29/26 |